Last reviewed · How we verify
HC022
At a glance
| Generic name | HC022 |
|---|---|
| Sponsor | HC Biopharma Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE (PHASE1)
- Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HC022 CI brief — competitive landscape report
- HC022 updates RSS · CI watch RSS
- HC Biopharma Inc. portfolio CI